Denosumab Reduced Fracture Risk in Trials

The studies were funded by Amgen. Dr. Cummings has received fees and/or grant support from Amgen, Eli Lilly, GlaxoSmithKline, Organon, Pfizer, and Novartis. Dr. Smith has received fees from Amgen, Novartis, and GTx. Their study associates work for, are invested in, and/or receive support from Amgen and other companies. Dr. Khosla reported having no potential conflicts of interest related to these topics. Dr. Dore reported receiving funding from Amgen for clinical trials, is a consultant to Amgen, and participates on their speakers bureau.

Denosumab use was not associated with jaw osteonecrosis or femoral shaft fractures seen with other agents.

Source DR. CUMMINGS